Gilead Sciences has allocated USD 200 million to potentially settle with federal prosecutors to resolve an investigation into ...

Gilead Sciences sets aside $200 million for a potential settlement over its HIV drug promotional speaker program amid federal investigation.

The major backer of the lenacapavir roll-out is assuring nervous researchers that they will keep their part of funding ...

Gilead Sciences set aside $200 million for a potential settlement with federal prosecutors to resolve an investigation into ...

The FDA has accepted under Priority Review the NDA for lenacapavir for the prevention of HIV as pre-exposure prophylaxis.

A revolutionary advancement in HIV prevention technology stands at a critical crossroads as recent policy decisions threaten ...

Several protesters were arrested Wednesday after U.S. Agency for International Development workers were told via a text ...

A groundbreaking injectable designed to curb the global spread of HIV is now at risk of being delayed due to Donald Trump's ...

Gilead Sciences has announced the European Medicines Agency’s (EMA) validation for a parallel accelerated review of ...

The discussion ended with a bold call to action for businesses, healthcare providers, and policymakers: health equity must be a priority—not just ethically, but economically. As Burgess put it: “This ...

The EMA is set to perform accelerated reviews of Gilead Sciences’ applications for its twice-yearly injectable for HIV ...

Missed KHOU 11+’s live Q&A on injectable PrEP? Watch on demand as experts discuss this HIV prevention breakthrough and answer ...